ES2869309T3 - Método para la conjugación de proteínas con tioéter - Google Patents

Método para la conjugación de proteínas con tioéter Download PDF

Info

Publication number
ES2869309T3
ES2869309T3 ES14818938T ES14818938T ES2869309T3 ES 2869309 T3 ES2869309 T3 ES 2869309T3 ES 14818938 T ES14818938 T ES 14818938T ES 14818938 T ES14818938 T ES 14818938T ES 2869309 T3 ES2869309 T3 ES 2869309T3
Authority
ES
Spain
Prior art keywords
protein
conjugation
reduction
solution
previous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14818938T
Other languages
English (en)
Spanish (es)
Inventor
Charlotte Schou Hunneche
Thomas Budde Hansen
Ernst Broberg Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk Health Care AG
Original Assignee
Novo Nordisk Health Care AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Health Care AG filed Critical Novo Nordisk Health Care AG
Application granted granted Critical
Publication of ES2869309T3 publication Critical patent/ES2869309T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES14818938T 2013-12-13 2014-12-15 Método para la conjugación de proteínas con tioéter Active ES2869309T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13197150 2013-12-13
PCT/EP2014/077777 WO2015086853A1 (en) 2013-12-13 2014-12-15 Method for thioether conjugation of proteins

Publications (1)

Publication Number Publication Date
ES2869309T3 true ES2869309T3 (es) 2021-10-25

Family

ID=49765887

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14818938T Active ES2869309T3 (es) 2013-12-13 2014-12-15 Método para la conjugación de proteínas con tioéter

Country Status (6)

Country Link
US (1) US11219690B2 (https=)
EP (1) EP3079722B1 (https=)
JP (1) JP6603662B2 (https=)
CN (1) CN106068127B (https=)
ES (1) ES2869309T3 (https=)
WO (1) WO2015086853A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102844773B1 (ko) 2015-12-23 2025-08-13 암젠 인크 위 억제 펩티드 수용체 (gipr)에 대한 결합 단백질을 glp-1 효능제와 조합하여 사용하여 대사 장애를 치료하거나 개선시키는 방법
BR112019014588A2 (pt) 2017-01-17 2020-02-18 Amgen Inc. Método de tratamento ou amenização de distúrbios metabólicos usando agonistas do receptor de glp-1 conjugados a antagonistas para receptor do peptídeo inibidor gástrico (gipr)
CN110831969B (zh) 2017-06-20 2024-06-21 安进公司 使用抑胃肽受体（gipr）结合蛋白与glp-1激动剂的组合治疗或改善代谢障碍的方法
MX2019015544A (es) 2017-06-21 2020-07-28 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de fusion de agonistas del receptor de glp-1/proteinas de union antagonistas para el receptor peptidico inhibidor gastrico (gipr).
FI3661562T3 (fi) * 2017-08-04 2024-12-09 Amgen Inc Cys-mab:ien konjugointimenetelmä

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
BR122013003013B8 (pt) * 1999-01-14 2021-07-06 Bolder Biotechnology Inc proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
IL152804A0 (en) 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
WO2004101597A2 (en) 2003-05-13 2004-11-25 Frutarom Ltd. Methods for the reduction of disulfide bonds
EP2033662B1 (en) 2004-01-21 2012-10-17 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
GB0513852D0 (en) 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
WO2007109475A2 (en) * 2006-03-16 2007-09-27 Bracco Imaging S.P.A. Chelation of metals to thiol groups using in situ reduction of disulfide-containing compounds by phosphines
CN101809032A (zh) 2007-08-24 2010-08-18 诺沃-诺迪斯克有限公司 用于选择性修饰蛋白质的方法
CN118767117A (zh) * 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
EP2536434B1 (en) 2010-02-16 2016-04-20 Novo Nordisk A/S Purification method
EP2595661A1 (en) 2010-07-22 2013-05-29 Novo Nordisk Health Care AG Growth hormone conjugates
EP3808378A1 (en) 2011-05-27 2021-04-21 Baxalta GmbH Therapeutic proteins with increased half-life and methods of preparing same
BR112014010406A2 (pt) * 2011-11-02 2017-04-25 Genentech Inc cromatografia de sobrecarga e eluto
CN103087183A (zh) * 2013-01-17 2013-05-08 南京邮电大学 一种光激发蛋白质中二硫键还原得到自由巯基的方法

Also Published As

Publication number Publication date
EP3079722A1 (en) 2016-10-19
CN106068127B (zh) 2020-06-19
WO2015086853A1 (en) 2015-06-18
CN106068127A (zh) 2016-11-02
US20160303248A1 (en) 2016-10-20
US11219690B2 (en) 2022-01-11
JP6603662B2 (ja) 2019-11-06
EP3079722B1 (en) 2021-03-24
JP2017501148A (ja) 2017-01-12

Similar Documents

Publication Publication Date Title
ES2869309T3 (es) Método para la conjugación de proteínas con tioéter
PT2100904E (pt) Fase sólida para utilização num método para a purificação de conjugados de albumina
Brocchini et al. Disulfide bridge based PEGylation of proteins
Gillespie et al. Structure and function of α-fetoprotein: a biophysical overview
ES2197373T3 (es) Fragmentos de anticuerpos monovalentes.
CN109071657B (zh) 包含双特异性抗体构建体的药物组合物
JP6023703B2 (ja) 改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
Zhang et al. Chromatographic separation of hemoglobin variants using robust molecularly imprinted polymers
Kragh-Hansen Human serum albumin: a multifunctional protein
NZ254661A (en) Polyethylene oxide/haemoglobin conjugates, fractionation thereof with anion exchangers
BR112013024706B1 (pt) Método para preparar análogos de exendina peguilada e análogo de exendina peguilada
RU2015135518A (ru) Гликомодифицированный предсердный натрийуретический пептид
JP4406169B2 (ja) ヘモグロビン−ハプトグロビン複合体
US11053278B2 (en) Tangential flow filtration based protein refolding methods
CN107108717B (zh) 一种可溶且稳定的异质二聚tcr
Savla et al. Structural stability and biophysical properties of the mega-protein erythrocruorin are regulated by polyethylene glycol surface coverage
EP1301075A1 (en) Modified serum albumin with reduced affinity for nickel and copper
Rahimizadeh et al. An albumin scaffold grafted with an alpha-helical motif delivers therapeutic payloads by modular coiled-coil assembly
JP2017501148A5 (https=)
Tuesca et al. Synthesis, characterization and in vivo efficacy of PEGylated insulin for oral delivery with complexation hydrogels
JP5713006B2 (ja) チオスルホナート化合物、タンパク質及び／又はペプチドの可逆的カチオン化剤並びに可溶化方法
CN101002944A (zh) 支链聚乙二醇－干扰素结合物及其制备方法
REBIZZI Development of releasable PEG for transient protein PEGylation
WO2020257712A1 (en) Granulocyte-macrophage colony-stimulating factor/elastin-like polypeptide fusion proteins and uses thereof
US20260021187A1 (en) Linkers